TJHA
NVCR icon

Thomas J. Herzfeld Advisors’s NovoCure NVCR Stock Holding History

Thomas J. Herzfeld Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-22
Closed -$1.32K – 343
2023
Q1 		$1.32K Hold
22
– – ﹤0.01% 314
2022
Q4 		$1.61K Hold
22
– – ﹤0.01% 307
2022
Q3 		$2K Hold
22
– – ﹤0.01% 290
2022
Q2 		$2K Hold
22
– – ﹤0.01% 297
2022
Q1 		$2K Hold
22
– – ﹤0.01% 310
2021
Q4 		$2K Buy
+22
New +$2.21K ﹤0.01% 348
2021
Q3 		– Sell
-22
Closed -$5K – 365
2021
Q2 		$5K Buy
+22
New +$4.28K ﹤0.01% 270

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return

Thomas J. Herzfeld Advisors's NVCR Position: Q2 2023 in Review

Thomas J. Herzfeld Advisors sold out of NovoCure (NVCR) in Q2 2023, closing a stake of 22 shares — an estimated $1.32K sold.

Thomas J. Herzfeld Advisors first reported a position in NVCR in Q2 2021 and held it in 7 quarters. The position peaked at $5K in Q2 2021. 267 funds tracked by Wall St. Rank hold NVCR as of Q2 2023.

  • Thomas J. Herzfeld Advisors reported no remaining NovoCure position as of Q2 2023 after selling out during the quarter.
  • Thomas J. Herzfeld Advisors sold 22 NovoCure shares in Q2 2023, an estimated $1.32K.
  • Thomas J. Herzfeld Advisors first reported a position in NovoCure in Q2 2021 and held it in 7 quarters.
  • Thomas J. Herzfeld Advisors's NovoCure position peaked at $5K in Q2 2021.
  • 267 funds tracked by Wall St. Rank held NovoCure as of Q2 2023.

Based on Thomas J. Herzfeld Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.